Login / Signup

A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.

A S PallerE C SiegfriedE L SimpsonM J CorkB LockshinM P KosloskiM A KamalJ D DavisX SunG PirozziN M H GrahamA GadkariLaurent EckertM RuddyAshish Bansal
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
Single-dose dupilumab was generally well tolerated and substantially reduced clinical signs/symptoms of AD. Slightly better responses were seen in older than younger children. The pharmacokinetics of dupilumab were non-linear, consistent with previous studies in adults and adolescents.
Keyphrases
  • atopic dermatitis
  • young adults
  • open label
  • physical activity
  • clinical trial
  • randomized controlled trial
  • middle aged
  • study protocol
  • community dwelling
  • radiation therapy